Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
Source: View publication →
The CONSENSUS trial demonstrated that the addition of enalapril to conventional therapy significantly reduced all-cause mortality in patients with severe (NYHA class IV) heart failure.
Key Findings
Study Design
Study Limitations
Clinical Significance
The CONSENSUS trial was a landmark study that established ACE inhibitors as a foundational, life-prolonging therapy for heart failure. It shifted the management paradigm from purely symptomatic relief (via digoxin and diuretics) to disease-modifying therapy, profoundly influencing subsequent clinical practice guidelines and the design of future heart failure trials.
Historical Context
Prior to 1987, the management of chronic heart failure relied heavily on digoxin and diuretics, with no intervention definitively proven to improve survival. The publication of CONSENSUS provided the first robust evidence that blocking the renin-angiotensin-aldosterone system (RAAS) with an ACE inhibitor could change the natural history of severe congestive heart failure, setting the stage for the broader application of neurohormonal blockade in cardiology.
Guided Discussion
High-yield insights from every perspective
What are the two primary hemodynamic mechanisms by which an ACE inhibitor like enalapril reduces the workload on the failing heart in severe congestive heart failure?
Key Response
ACE inhibitors reduce afterload by inhibiting the production of Angiotensin II, a potent vasoconstrictor, and reduce preload by decreasing aldosterone secretion, which leads to less sodium and water retention. In severe HF, reducing both the resistance the heart must pump against and the volume it must handle is critical for improving cardiac output.
In the CONSENSUS trial, nearly half of the patients were receiving potassium-sparing diuretics at baseline. When initiating enalapril in a patient with NYHA Class IV heart failure today, what specific laboratory monitoring schedule and clinical precautions should be prioritized?
Key Response
Initiating ACE inhibitors in severe HF (NYHA IV) carries a high risk of first-dose hypotension and acute kidney injury, especially in patients already on high-dose loop diuretics. Potassium and creatinine should be checked within 1-2 weeks of initiation and after every dose titration to monitor for hyperkalemia and decreased GFR, particularly if the patient is also on a mineralocorticoid receptor antagonist (MRA).
While CONSENSUS demonstrated a 31% reduction in all-cause mortality at one year, the reduction was primarily driven by a decrease in deaths from 'progression of heart failure' rather than 'sudden cardiac death.' How does this finding inform our current multi-drug GDMT approach for HFrEF?
Key Response
This finding highlights that while ACE inhibitors effectively slow the mechanical and neurohormonal progression of heart failure, they do not provide the same level of protection against ventricular arrhythmias as beta-blockers or mineralocorticoid receptor antagonists. This necessitates a 'quadruple therapy' approach to cover all pathways of mortality, including sudden cardiac death.
CONSENSUS marked the shift from a 'hemodynamic' model of heart failure to a 'neurohormonal' model. How should this historical context be used to teach trainees about the evolution from symptom-based therapy to disease-modifying therapy?
Key Response
Before CONSENSUS, heart failure was treated like a plumbing problem with diuretics and inotropes (digoxin) to improve symptoms. CONSENSUS was the first trial to show that blocking a hormonal pathway (RAAS) could actually extend life, teaching us that the body's compensatory mechanisms are themselves the drivers of disease progression.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The CONSENSUS trial was stopped early by the ethical review committee due to the significant benefit observed in the enalapril group. What are the potential statistical implications regarding the 'magnitude of effect' when a trial is terminated early for benefit?
Key Response
Stopping a trial early for benefit can lead to an overestimation of the treatment effect, often referred to as 'the winner's curse' or 'random highs.' In a relatively small trial (n=253), early termination increases the likelihood that the reported hazard ratio is more favorable than it would have been if the trial had reached its full planned duration.
Given the small sample size of 253 patients, what aspects of the trial design and patient selection allowed CONSENSUS to achieve the statistical power necessary for publication in a top-tier journal like NEJM?
Key Response
The investigators selected a very high-risk population (NYHA Class IV only), ensuring a high event rate. In such a cohort, even a small number of participants can generate enough endpoints to show a statistically significant difference if the intervention is highly effective. The mortality rate in the placebo group was 52% at one year, providing immense power to detect the 31% reduction.
How do the findings of CONSENSUS regarding ACE inhibitors in severe HF align with current 2022 AHA/ACC/HFSA guidelines, particularly concerning the transition to Angiotensin Receptor-Neprilysin Inhibitors (ARNI)?
Key Response
CONSENSUS established ACE inhibitors as a Class 1 recommendation (Level A evidence). However, modern guidelines (2022 AHA/ACC/HFSA) now prioritize ARNI (Class 1, Level A) over ACE inhibitors for patients with HFrEF because trials like PARADIGM-HF showed superior mortality reduction compared to enalapril. ACE inhibitors are now recommended only when ARNI is not feasible, reflecting the evolution of the evidence base CONSENSUS started.
Clinical Landscape
Noteworthy Related Trials
SOLVD-Treatment Trial
Tested
Enalapril
Population
Patients with symptomatic heart failure and ejection fraction <= 35%
Comparator
Placebo
Endpoint
All-cause mortality
V-HeFT II Trial
Tested
Enalapril
Population
Patients with chronic heart failure
Comparator
Hydralazine-isosorbide dinitrate
Endpoint
All-cause mortality
SAVE Trial
Tested
Captopril
Population
Patients with left ventricular dysfunction following myocardial infarction
Comparator
Placebo
Endpoint
All-cause mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis